Overview

Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Status:
Active, not recruiting

Trial end date:
2022-01-01

Target enrollment:

Participant gender:

Summary

This is a Phase 3 study to evaluate the objective response rate (ORR), in patients with metastatic pancreatic ductal adenocarcinoma treated with relacorilant in combination with nab-paclitaxel, according to blinded independent central review.

Phase:

Phase 3

Details

Lead Sponsor:

Corcept Therapeutics

Treatments:

Albumin-Bound Paclitaxel
Paclitaxel